Nasdaq Up 1%; Meta Shares Surge Following Upbeat Results
Portfolio Pulse from Lisa Levin
U.S. stocks traded higher with the Nasdaq Composite gaining around 1%. Meta Platforms, Inc. (NASDAQ:META) shares jumped 7% after reporting better-than-expected Q2 results. Carmell Therapeutics Corporation (NASDAQ:CTCX) shares shot up 41% after announcing a merger with Axolotl Biologix. Femasys Inc. (NASDAQ:FEMY) shares shot up 174% after the US Patent and Trademark Office issued a Notice of Allowance for FemBloc. North American Construction Group Ltd. (NYSE:NOA) shares were up 38% after posting better-than-expected Q2 results. Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares dropped 77% after UPLIFT clinical trial did not meet primary endpoint. TPI Composites, Inc. (NASDAQ:TPIC) shares were down 35% after lowering its 2023 forecast. Asensus Surgical, Inc. (NYSE:ASXC) shares fell 35% after reporting a $10 million registered direct offering.
July 27, 2023 | 4:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Carmell Therapeutics shares shot up 41% after announcing a merger with Axolotl Biologix.
The announcement of the merger with Axolotl Biologix has positively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Femasys shares shot up 174% after the US Patent and Trademark Office issued a Notice of Allowance for FemBloc.
The issuance of a Notice of Allowance for FemBloc by the US Patent Office has positively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Meta Platforms shares jumped 7% after reporting better-than-expected Q2 results.
The company's better-than-expected Q2 results have positively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
North American Construction Group shares were up 38% after posting better-than-expected Q2 results.
The company's better-than-expected Q2 results have positively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Asensus Surgical shares fell 35% after reporting a $10 million registered direct offering.
The company's announcement of a $10 million registered direct offering has negatively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Mersana Therapeutics shares dropped 77% after UPLIFT clinical trial did not meet primary endpoint.
The failure of the UPLIFT clinical trial to meet its primary endpoint has negatively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
TPI Composites shares were down 35% after lowering its 2023 forecast.
The company's decision to lower its 2023 forecast has negatively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100